Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Sees Significant Growth in Short Interest

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) was the target of a significant increase in short interest in July. As of July 15th, there was short interest totaling 1,448,757 shares, an increase of 74.6% from the June 30th total of 829,522 shares. Currently, 1.9% of the company’s stock are sold short. Based on an average daily volume of 1,113,100 shares, the short-interest ratio is currently 1.3 days.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nautilus Biotechnology in a research report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Nautilus Biotechnology presently has a consensus rating of “Hold” and an average price target of $4.00.

Insider Activity at Nautilus Biotechnology

In other news, major shareholder Ah Equity Partners Bio Ii, L.L sold 5,000,000 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $2.35, for a total transaction of $11,750,000.00. Following the completion of the sale, the insider owned 971,885 shares in the company, valued at approximately $2,283,929.75. This represents a 83.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 41.10% of the company’s stock.

Institutional Trading of Nautilus Biotechnology

A number of hedge funds have recently modified their holdings of the stock. Bank of America Corp DE grew its holdings in Nautilus Biotechnology by 37.1% during the fourth quarter. Bank of America Corp DE now owns 49,419 shares of the company’s stock worth $83,000 after acquiring an additional 13,363 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in Nautilus Biotechnology in the 1st quarter worth approximately $194,000. Acadian Asset Management LLC grew its stake in shares of Nautilus Biotechnology by 468.3% during the 1st quarter. Acadian Asset Management LLC now owns 61,735 shares of the company’s stock worth $51,000 after purchasing an additional 50,871 shares during the period. XTX Topco Ltd increased its holdings in shares of Nautilus Biotechnology by 86.2% during the 2nd quarter. XTX Topco Ltd now owns 66,194 shares of the company’s stock valued at $48,000 after purchasing an additional 30,641 shares in the last quarter. Finally, Qube Research & Technologies Ltd acquired a new position in shares of Nautilus Biotechnology in the 2nd quarter valued at $45,000. Hedge funds and other institutional investors own 50.71% of the company’s stock.

Nautilus Biotechnology Price Performance

NAUT traded down $0.04 during trading on Friday, reaching $0.98. 571,029 shares of the company’s stock were exchanged, compared to its average volume of 486,447. Nautilus Biotechnology has a 1 year low of $0.62 and a 1 year high of $4.31. The company’s fifty day simple moving average is $2.05 and its 200-day simple moving average is $2.43. The stock has a market capitalization of $125.35 million, a P/E ratio of -2.20 and a beta of 0.80.

Nautilus Biotechnology (NASDAQ:NAUT) last released its quarterly earnings data on Tuesday, July 28th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. The business had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.10 million.

About Nautilus Biotechnology

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.